Evaluation of Intravenous Dalbavancin for Peritonitis

University of Colorado Denver (CU Denver)

Status: Terminated

Conditions: Peritonitis Bacterial; Peritonitis

Treatments: Drug: Dalbavancin

Study type: Observational

Funder types: Other

Identifiers

NCT04624451

19-1731

Details and patient eligibility

About

This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients > 18 years of age actively receiving peritoneal dialysis diagnosed with a gram + peritonitis determined to be a good candidate for dalbavancin treatment by the attending nephrology attending.

Exclusion criteria

Patients with contraindications to dalbavancin therapy